• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·SNY
Held by 3 Gurus
Share

Sanofi Stocks

$ 40.94Last Updated 24.09.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 99.84B

$ 40.94
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.0%

Change

+0.04%

Fund

Point72 Asset Management, L.P.

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.04%

Fund

Bridgewater Associates

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.0%+0.04%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.04%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Latest news

24.07.2026 14:59

IPO Scribe: Shares in a biotech company backed by Eli Lilly and Sanofi are now available

23.06.2026 00:29

AbbVie will acquire a psoriasis drug developer for $11 billion. Its stock rose 47%.

06.02.2026 15:00

Agomab Therapeutics IPO: Pfizer and Sanofi-backed biotech starts trading

24.12.2025 16:58

Sanofi is expanding its vaccine business. It will buy Dynavax for $2.2 billion

15.12.2025 19:23

Sanofi's stock is down. Its sclerosis drug suffers 'double blow'

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of SNY is 51.7 and suggests 26.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.09.2026 17:11

Romania borrowed $600 million from the public through the "blood-for-bonds" program

25.09.2026 16:45

Western, Barbie, and Alpine Skiing: What Will Help Wrangler's Stock Rise 50%?

25.09.2026 16:11

Shares of CareDx, a medical test developer, soared to a 5-year high. Why?

25.09.2026 15:45

"Hacker Club" Incidents: How Errors in AI Tests Created New Risks for Investors

25.09.2026 15:30

BlackRock sees Kazakhstan and Uzbekistan as new investment hubs

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026